SONN Sonnet BioTherapeutics Holdings Inc.: Enterprise Value-to-Revenue Multiple

Public company logo of Sonnet BioTherapeutics Holdings, Inc. (SONN)

The pursuit of agreements with pharma behemoths is driving growth, as evidenced by the current price-to-sales valuation of Sonnet BioTherapeutics (SONN). 8670.00 reflects the most recent value of this metric. The business foundation is the FHAB platform, which extends cytokine activity via albumin. Top biochemists lead the development, supported by substantial funding and comprehensive benefits packages. This chart helps identify zones of fundamental undervaluation or overvaluation of SONN assets.

Company Value to Revenue: Sonnet BioTherapeutics Holdings Inc. (SONN) for 11/23/2025 - 12/13/2025

Sonnet BioTherapeutics Holdings Inc. - analytical breakdowns and key metrics (SONN)

- share price and consensus valuation forecast:
- money and cash flow information:
Product sample of Sonnet BioTherapeutics Holdings, Inc.

For Sonnet BioTherapeutics (SONN), this indicator links market capitalization to the monetization efficiency of unique protein modification methods in immunotherapy. By analyzing the historical EV/Sales trend, an investor assesses the total enterprise value minus net debt relative to revenue, where sharp deviations of the curve from fundamentals signal speculative overheating and the risk of an asset correction.

Competitor analysis for Sonnet BioTherapeutics

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP